SYNLOGIC, INC. Stock Issued During Period, Value, Employee Stock Purchase Plan
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- SYNLOGIC, INC. stock issued during period, value, employee stock purchase plan for the quarter ending 2023-12-31 was $0.00.
- SYNLOGIC, INC. stock issued during period, value, employee stock purchase plan for the quarter ending 2023-09-30 was $65.00K, a 20.37% increase year-over-year.
- SYNLOGIC, INC. stock issued during period, value, employee stock purchase plan for the quarter ending 2023-06-30 was $0.00.
- SYNLOGIC, INC. stock issued during period, value, employee stock purchase plan for the quarter ending 2023-03-31 was $59.00K, a 28.92% decline year-over-year.
- SYNLOGIC, INC. stock issued during period, value, employee stock purchase plan for fiscal 2023 was $124.00K, a 9.49% decline from fiscal 2022.
- SYNLOGIC, INC. stock issued during period, value, employee stock purchase plan for fiscal 2022 was $137.00K, a 45.74% increase from fiscal 2021.
- SYNLOGIC, INC. stock issued during period, value, employee stock purchase plan for fiscal 2021 was $94.00K, a 123.81% increase from fiscal 2020.
- SYNLOGIC, INC. stock issued during period, value, employee stock purchase plan for fiscal 2020 was $42.00K.
| Period end | Stock Issued During Period, Value, Employee Stock Purchase Plan 3 month | Stock Issued During Period, Value, Employee Stock Purchase Plan 12 month |
|---|---|---|
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $124.00K 10-K · filed 2025-03-06 |
| 2023-09-30 | $65.00K 10-Q · filed 2024-11-12 | $124.00K derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $113.00K derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $59.00K 10-Q · filed 2024-05-14 | $113.00K derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | $137.00K 10-K · filed 2024-03-19 |
| 2022-09-30 | $54.00K 10-Q · filed 2023-11-09 | $137.00K derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $144.00K derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $83.00K 10-Q · filed 2023-05-11 | $144.00K derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | $94.00K 10-K · filed 2023-03-29 |
| 2021-09-30 | $61.00K 10-Q · filed 2022-11-10 | $94.00K derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $75.00K derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $33.00K 10-Q · filed 2022-05-12 | |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $42.00K 10-K · filed 2022-03-17 |
| 2020-09-30 | $42.00K 10-Q · filed 2021-11-10 | |
| 2016-12-31 | $7.00K 10-K · filed 2017-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |